Institute of Medicine's new drug safety report: implications for Canada

Cassels, Alan
December 2006
CMAJ: Canadian Medical Association Journal;12/5/2006, Vol. 175 Issue 12, p1515
Academic Journal
The article focuses on the implications of a drug safety report released by the U.S. Institute of Medicine (IOM) in 2006 for Canada. Information is presented concerning the preventable adverse drug events in the U.S. based on the IOM report. Several recommendations are stated in the report including clearer authority for the U.S. Food and Drug Administration and additional tools for enforcement.


Related Articles

  • IOM: FDA Needs Revamped Regulatory Framework.  // Chain Drug Review;6/7/2010, Vol. 32 Issue 10, p236 

    The article reports on the suggestions made by the Institute of Medicine to Food & Drug Administration (FDA) suggesting the revamp of its regulatory framework in the evaluation of food benefits and nutritional supplements in Washington.

  • IOM report scolds FDA, suggests DTC ban. Arnold, Matthew // Medical Marketing & Media;Nov2006, Vol. 41 Issue 11, p32 

    The article examines the report issued by the U.S. Institute of Medicine concerning the direct-to-consumer drug advertising issue. The institute criticizes the failure of the Food and Drug Administration to control and implement rules covering the advertising of drugs. The report also suggests...

  • Committee releases recommendations for the FDA.  // Reactions Weekly;9/30/2006, Issue 1121, p3 

    The article focuses on the recommendations issued by the Institute of Medicine to the U.S. Food and Drug Administration regarding processes involved in drug approval and marketing. The recommendations include advertising limits and labeling requirements for new medications. Labeling of new...

  • The IOM Report. Agnes, Ted // Drug Discovery & Development;Nov2006, Vol. 9 Issue 11, p16 

    The article focuses on the report from the Institute of Medicine (IOM) inferring that the U.S. Food and Drug Administration (FDA) is suffering from a dysfunctional organizational culture in which the stress on reviewing new drugs for market approval outweighs the monitoring and assessing of...

  • Antibiotics and superbugs. McConnell, Harvey // Futurist;Feb99, Vol. 33 Issue 2, p9 

    Focuses on antibiotics and superbugs in the United States (US). Information on the report from the Institute of Medicine in Washington, D.C. on the widespread use of antibiotics in food animals; Factors that can contribute to the development of drug resistance; Antibiotics approved by the US...

  • The US FDA requires a "new vision of drug safety.".  // Reactions Weekly;11/4/2006, Issue 1126, p3 

    The article reports on the recommendation of the Institute of Medicine Committee on the Assessment of the U.S. Drug Safety System for U.S. Food and Drug Administration to acquire a culture of safety in which the risks and benefits of medications are examined during their entire market life. The...

  • Laws Boost Pediatric Clinical Trials, But Report Finds Room for Improvement. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;4/25/2012, Vol. 307 Issue 16, p1681 

    The article discusses a report from the Institute of Medicine (IOM) which recognizes that laws boost pediatric clinical trials of medications and also identified the need for improvements such as greater transparency about trial results and clarity about the potential benefits a trial may offer...

  • Institute of Medicine Report Slams FDA.  // Quality Progress;Nov2006, Vol. 39 Issue 11, p16 

    The article reports on an independent federal report from the United States Institute of Medicine. The report echoes the harshest critics of the U.S. Food and Drug Administration's drug safety regimen. According to the report, the drug safety system of the country is feeble in its drug approval...

  • IOM head says stronger FDA is needed. Dickinson, James C. // Medical Marketing & Media;May2008, Vol. 43 Issue 5, p12 

    The article informs that according to Institute of Medicine (IOM) president, Harvey Fineberg, the U.S. Food and Drug Administration (FDA), needs to be stronger in order to enhance the speed and effectiveness of personalised medicine. Fineberg believes that it would be hard for FDA to meet the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics